Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Levels of Sirolimus in saliva vs. blood--the rationale of topical oral use for oral malignancy.

Nudelman Z, Keshet N, Elhalal MD, Friedman M, Czerninski R.

Anticancer Res. 2013 Feb;33(2):661-3.

PMID:
23393364
2.

Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application.

Nudelman Z, Findler M, Barasch D, Nemirovski A, Pikovsky A, Kirmayer D, Basheer M, Gutkind JS, Friedman M, Czerninski R.

Cancer Chemother Pharmacol. 2015 May;75(5):969-74. doi: 10.1007/s00280-015-2721-z. Epub 2015 Mar 11.

PMID:
25757961
3.

Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring.

Holt DW, Mandelbrot DA, Tortorici MA, Korth-Bradley JM, Sierka D, Levy DI, See Tai S, Horowitz GL.

Clin Transplant. 2014 Feb;28(2):243-51. doi: 10.1111/ctr.12305. Epub 2014 Jan 30.

PMID:
24476346
4.

Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.

Coentrão L, Carvalho C, Sampaio S, Oliveira JG, Pestana MI.

Transplant Proc. 2010 Jun;42(5):1867-9. doi: 10.1016/j.transproceed.2010.01.059.

PMID:
20620539
5.

Levels of sirolimus in saliva and blood following mouthwash application.

Nudelman Z, Friedman M, Barasch D, Nemirovski A, Findler M, Pikovsky A, Gutkind J, Czerninski R.

Oral Dis. 2014 Nov;20(8):768-72. doi: 10.1111/odi.12229. Epub 2014 Mar 24.

PMID:
24548545
6.

Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Jiao Z, Shi XJ, Li ZD, Zhong MK.

Br J Clin Pharmacol. 2009 Jul;68(1):47-60. doi: 10.1111/j.1365-2125.2009.03392.x.

7.

Everolimus: an immunosuppressive agent in transplantation.

Patel JK, Kobashigawa JA.

Expert Opin Pharmacother. 2006 Jul;7(10):1347-55. Review.

PMID:
16805720
8.

A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection.

Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ.

J Clin Pharmacol. 2006 Jan;46(1):76-87.

PMID:
16397287
9.

Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.

Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.

Transplantation. 2010 Apr 27;89(8):994-1000. doi: 10.1097/TP.0b013e3181ccd7f2.

PMID:
20335831
10.

Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.

Ettenger RB, Grimm EM.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8. Review.

PMID:
11583941
11.

Sirolimus: has it gained from experience with older drugs?

Holt DW.

Therapie. 2002 Mar-Apr;57(2):128-32.

PMID:
12185960
12.

Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.

Perrakis A, Schwarz K, Yedibela S, Croner RS, Hohenberger W, Müller V.

Transplant Proc. 2011 Dec;43(10):3702-7. doi: 10.1016/j.transproceed.2011.09.015.

PMID:
22172830
13.
14.

Considerations in sirolimus use in the early and late post-transplant periods.

Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.

Expert Opin Drug Saf. 2009 Jul;8(4):421-34. doi: 10.1517/14740330903037156. Review.

PMID:
19522662
15.

Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results.

Ferreira AN, Machado PG, Felipe CR, Motegi SA, Hosaka BH, Tanaka MK, Kamura LA, Park SI, Garcia R, Franco M, Alfieri F, Casarini DE, Tedesco-Silva H Jr, Medina-Pestana JO.

Clin Transplant. 2005 Oct;19(5):607-15.

PMID:
16146551
16.

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.

Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group.

Transplantation. 2002 Dec 15;74(11):1560-7.

PMID:
12490789
17.

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

MacDonald A, Scarola J, Burke JT, Zimmerman JJ.

Clin Ther. 2000;22 Suppl B:B101-121. Review.

PMID:
10823378
18.

Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.

Machado PG, Felipe CR, Park SI, Garcia R, Moreira S, Casarini D, Franco M, Alfieri F, Tedesco-Silva H Jr, Medina-Pestana JO.

Braz J Med Biol Res. 2004 Sep;37(9):1303-12. Epub 2004 Aug 24.

19.

Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer.

Schmid RW, Lotz J, Schweigert R, Lackner K, Aimo G, Friese J, Rosiere T, Dickson D, Kenney D, Maine GT.

Clin Biochem. 2009 Oct;42(15):1543-8. doi: 10.1016/j.clinbiochem.2009.06.018. Epub 2009 Jun 27.

PMID:
19563794
20.

Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus.

Villanueva J, Boukhamseen A, Bhorade SM.

J Heart Lung Transplant. 2005 Apr;24(4):421-5.

PMID:
15797743
Items per page

Supplemental Content

Write to the Help Desk